Non Small Cell Lung Carcinoma
Conditions
Keywords
Locally Advanced Non Small Cell Lung Cancer (Stage IIIA and IIIB)
Brief summary
The aim of the study if to determine if Iressa can prolong the period of time without any disease worsening (Time to progression) in patients previously treated with combined therapy such as surgery and chemotherapy with or without radiotherapy or chemotherapy and radiotherapy
Interventions
Sponsors
AstraZeneca
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically Confirmed Non Small Cell Lung Cancer. * Locally advanced disease previously treated with combined therapy (chemotherapy and surgery with or without radiotherapy, or chemotherapy and radiotherapy). * Chemotherapy with regimens containing cisplatin or carboplatin is mandatory * Response to combined therapy
Exclusion criteria
* No previous treatment with ZD1839 or any other EGFR-targeted therapy * No progressive disease after combined therapy for locally advanced NSCLC * No presence of metastatic disease * No other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ * Any unresolved chronic toxicity from previous anticancer therapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to progression (2 years after Last patient in) | — |
Secondary
| Measure | Time frame |
|---|---|
| Modalities of relapse or progression (2 years after Last patient in) | — |
| Overall survival (2 years after Last patient in) | — |
Countries
Italy
Outcome results
None listed